India using Kashmir to oppose Silk Road project: Chinese media

March 30, 2017

Beijing, Mar 30: India sees China's Silk Road initiative as a geopolitical competition and is using the Kashmir issue as an "unfounded excuse" to oppose the ambitious project, Chinese state media today alleged and asked New Delhi to "abandon" its "cliche mentality".

"The official reason the Indian government rejected the offer to join the initiative (Silk Road) is that it is designed to pass through Kashmir. However, it is just an unfounded excuse as Beijing has been maintaining a consistent position on the Kashmir issue, which has never changed," one of the two articles on India by state-run Global Times said.

China1"India sees the Belt and Road initiative as a geopolitical competition," the article said, criticising India for hindering Beijing's push into South Asia and the world with multi-billion Silk Road project which is also known as the 'Belt and Road' (BR).

"Whether to continue to boycott or join the Belt and Road remains a conundrum for New Delhi," it said adding that, India is the only one which can help itself. The article said that India should give up its "biased" view on the BR initiative. "It is high time to abandon the cliche mentality of associating everything with geopolitics.

India will surely see a different world if it does," the article said. Referring to India's reservations to attend the BR summit called by Chinese President Xi Jinping, the article said it may be an "embarrassing occasion" for India as the meeting is backed by "China's peripheral countries, notably Russia, Indonesia, Kazakhstan and Pakistan".

Chinese Foreign Minister Wang Yi recently said 20 heads of state will attend the summit, together with over 50 leaders from international organisations, over 100 ministerial officials and more than 1,200 guests from around the world.

The article referred to a comment by Foreign Secretary S Jaishankar during his visit here last month to co-chair the upgraded India-China strategic dialogue, saying India is examining China's invitation to attend the summit and "how a country whose sovereignty has been violated can come on aninvitation".

In the meantime, however, state-run Chinese media stepped up campaign to pressurise India to join the summit. China apparently is keen about India's participation in the summit as the project struggled to make headway in the region except the USD 46 billion China Pakistan Economic Corridor (CPEC) where both Beijing-Islamabad are putting all efforts to show early harvest.

Media reports here said that Xi plans to invite his US counterpart Donald Trump to attend the meeting during their first summit early next month in Florida. BR consisted of maze of roads, including CPEC, Bangladesh-China-India-Myanmar Economic (BCIM) Corridor and 21st Maritime Silk Road besides road network to connect China with Eurasia.

The article also said, "it seems that the mainstream opinion throughout India is that the connectivity brought about by BR initiative is geopolitically significant. Therefore, India cannot allow the initiative to expand further into South Asia".

"This could also explain why the BCIM has seen no progress since its proposed by Chinese Premier Li Keqiang in 2013, and also why New Delhi has been keen on Japan's investment in the Iranian port of Chabahar," it said.

"New Delhi may also feel embarrassed as Moscow has actively responded to the Belt and Road initiative and will build an economic corridor with China and Mongolia," it said, adding Russia and Iran seeking to join the CPEC putting "India in a more awkward position".

It said, "Beijing has expressed, on various occasions, its anticipation to see New Delhi join the grand project and to make concerted effort with India in building economic corridors involving China, India, Sri Lanka, Nepal, Bangladesh and Myanmar".

Another article in the same daily said a "benign" competition between India and China may help development in South Asia but they should avoid "cut-throat" rivalry. "The so-called dragon-elephant contention is perhaps a blow against strategic mutual trust between Beijing and New Delhi, but may be conducive to development in South Asia," it said.

Accusing India of not being "generous" to its neighbours, it said "a yawning infrastructure funding gap in South Asian countries creates space for China and those nations to strengthen economic cooperation".

"Bangladesh and China signed 27 deals worth billions of dollars during President Xi Jinping's visit last year," it said, adding China's BR initiative has received an increasing amount of attention from Bangladesh.

"Only by investing more resources in regional integration and extending the benefits from India's rapid economic growth to other South Asian countries can New Delhi maintain its influence in the region," it said.

"Benign competition between China and India will be conducive to development in South Asia. The question remaining is how to avoid cut-throat competition as Beijing and New Delhi jostle for influence. India and China should seek common ground while strengthening cooperation with South Asian countries to promote regional integration," it said.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
June 4,2020

Beijing, Jun 4: Around 40 students and staff members of a primary school in China were stabbed by a security guard, official media reported today.

The incident happened at a school in China's Guangxi province, state-run China Daily said in a brief report.

Further details about the attack are awaited.

Knife attacks by disgruntled people have been taking place in different parts of China in the past few years, reported news agency Press Trust of India.

The attackers targeted mainly kindergarten and primary schools besides public transport, the news agency reported.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
March 16,2020

Manila, Mar 16: The Philippines has detected an outbreak of avian flu in a northern province after tests showed presence of the highly infectious H5N6 subtype of the influenza A virus in a quail farm, the country's farm minister said on Monday.

Agriculture Secretary William Dar said the bird flu virus, the same strain that hit some local poultry farms in 2017, was detected in Jaen municipality in Nueva Ecija province, where about 1,500 quails had died on one farm alone.

A total of 12,000 quails have been destroyed and buried to prevent further infections, Dar said, citing field reports.

"We are on top of the situation," he said. "Surveillance around the 1-km and 7-km radius will be carried out immediately to ensure that the disease has not progressed around the said perimeter."

Animal quarantine checkpoints have also been set up to restrict the movement of all live domestic birds to and from the quarantine area, he said.

"We would like to emphasise that this is a single case affecting one quail farm only," Dar said.

Dr. Arlene Vytiaco, technical spokeswoman for avian flu at the agriculture department, said that while there is a possibility of transmission to humans through excretion and secretion, "the chances are very slim".

"There is also zero mortality rate," she said.

Dar said his department and the local government were jointly conducting an investigation and contact-tracing to determine the source of infection.

To ensure steady domestic supply of poultry, he said the transport of day-old chicks, hatching eggs and chicken meat will be allowed provided the source farms have tested negative for bird flu.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
March 4,2020

Beijing/Zurich, Mar 4: China has approved the use of Swiss drugmaker Roche's anti-inflammation drug Actemra for patients who develop severe complications from the coronavirus as it urgently hunts for new ways to combat the deadly infection that is spreading worldwide.

China is hoping that some older drugs could stop severe cytokine release syndrome (CRS), or cytokine storms, an overreaction of the immune system which is considered a major factor behind catastrophic organ failure and death in some coronavirus patients.

Actemra, a biologic drug approved in 2010 in the United States for rheumatoid arthritis (RA), inhibits high Interleukin 6 (IL-6) protein levels that drive some inflammatory diseases.

China's National Health Commission said in treatment guidelines published online on Wednesday that Actemra can now be used to treat coronavirus patients with serious lung damage and high IL-6 levels.

Separately, researchers in the country are testing Actemra, known generically as tocilizumab, in a clinical trial expected to include 188 coronavirus patients and running until May 10.

Roche, which donated 14 million yuan ($2.02 million) worth of Actemra during February, said the trial was initiated independently by a third party with the aim of exploring the efficacy and safety of the drug in coronavirus patients with CRS.

It added that there was currently no published clinical trial data on the drug's safety or efficacy against the virus.

More than 3,000 people have died and 93,000 have been infected by the novel coronavirus thought to have originated in Wuhan, China, before spreading to around 90 countries including the United States, Italy, Switzerland, France and Germany.

The Swiss company, for which China is its No. 2 market behind the United States, also makes diagnostic gear to detect the coronavirus.

Since Actemra's approval a decade ago, it has become a go-to drug against other inflammatory conditions, including cytokine storms in cancer patients receiving cell therapies from Novartis and Gilead Sciences.

In 2012 it helped save the life of a young U.S. girl, the first child to be treated for leukaemia with Novatis' Kymriah, from a post-treatment rush of IL-6.

Priced at between $20-30,000 annually for RA according to SSR Health, Roche's medicine is also used for rare juvenile arthritis and giant cell arteritis, or inflammation of the blood vessels.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.